Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago. These ...

Stoke Therapeutics Inc (NASDAQ:STOK) is set to release its Q2 2025 earnings on Aug 12, 2025. The consensus estimate for Q2 ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...

Wrexham ’s historic Racecourse Ground will become known as the SToK Racecourse under the terms of a new sponsorship deal brokered by Hollywood owners Ryan Reynolds and Rob McElhenney. This is ...